Evolvere BioSciences

About Evolvere BioSciences

Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.

<problem> The rise of antibiotic-resistant bacteria poses a significant threat to global health, rendering many existing antibiotics ineffective. Traditional antibiotic development struggles to keep pace with the rapid evolution of pathogens, leading to a critical need for new strategies. </problem> <solution> Evolvere BioSciences employs artificial intelligence and co-evolutionary modeling to design novel antibiotics that can overcome bacterial resistance mechanisms. Their approach simulates the evolutionary arms race between bacteria and antibiotics, allowing them to predict and preempt resistance development. By understanding how bacteria evolve in response to drugs, Evolvere BioSciences can create antibiotics that remain effective over longer periods. This proactive strategy aims to provide a sustainable solution to the growing problem of antibiotic resistance. </solution> <features> - AI-driven co-evolutionary models to predict and preempt bacterial resistance - In silico drug design to identify novel antibiotic candidates - High-throughput screening to validate antibiotic efficacy against resistant strains - Optimization of drug candidates for improved potency and pharmacokinetic properties </features> <target_audience> The primary target audience includes pharmaceutical companies, research institutions, and government agencies involved in antibiotic development and combating antimicrobial resistance. </target_audience>

What does Evolvere BioSciences do?

Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.

Where is Evolvere BioSciences located?

Evolvere BioSciences is based in Oxford, United Kingdom.

When was Evolvere BioSciences founded?

Evolvere BioSciences was founded in 2021.

How much funding has Evolvere BioSciences raised?

Evolvere BioSciences has raised $500.0K.

Location
Oxford, United Kingdom
Founded
2021
Funding
$500.0K
Employees
6 employees
Investors
Y Combinator

Evolvere BioSciences

10
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Evolvere BioSciences utilizes AI-driven co-evolutionary models to develop next-generation antibiotics that effectively combat bacterial resistance. This approach addresses the critical challenge of antibiotic efficacy in the face of rapidly evolving pathogens.

evolverebiosciences.com700+
Founded 2021 – Oxford, United Kingdom

Funding

No specific funding rounds found.

Total Funding

$500.0K

Backed by

Y Combinator

Team (5+)

No team information available.

Company Description

Problem

The rise of antibiotic-resistant bacteria poses a significant threat to global health, rendering many existing antibiotics ineffective. Traditional antibiotic development struggles to keep pace with the rapid evolution of pathogens, leading to a critical need for new strategies.

Solution

Evolvere BioSciences employs artificial intelligence and co-evolutionary modeling to design novel antibiotics that can overcome bacterial resistance mechanisms. Their approach simulates the evolutionary arms race between bacteria and antibiotics, allowing them to predict and preempt resistance development. By understanding how bacteria evolve in response to drugs, Evolvere BioSciences can create antibiotics that remain effective over longer periods. This proactive strategy aims to provide a sustainable solution to the growing problem of antibiotic resistance.

Features

AI-driven co-evolutionary models to predict and preempt bacterial resistance

In silico drug design to identify novel antibiotic candidates

High-throughput screening to validate antibiotic efficacy against resistant strains

Optimization of drug candidates for improved potency and pharmacokinetic properties

Target Audience

The primary target audience includes pharmaceutical companies, research institutions, and government agencies involved in antibiotic development and combating antimicrobial resistance.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.
Evolvere BioSciences - Funding: $500.0K | StartupSeeker